MedTrace Logo

Lindera Obtusiloba for Non-small Cell Lung Cancer

NCT04348149 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-04-16

No results posted yet for this study

Summary

This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DIETARY_SUPPLEMENT

Lindera obtusiloba extract

One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.

Sponsors & Collaborators

  • Korea Institute of Oriental Medicine

    collaborator OTHER_GOV

  • Jun-Yong Choi

    lead OTHER

Principal Investigators

  • Jun-Yong Choi, KMD/PHD · Korean Medicine Hospital of Pusan National University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-28
Primary Completion
2020-12-27
Completion
2020-12-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04348149 on ClinicalTrials.gov